NICE - Endorsed Technology Appraisals 2024/2025

It is important to note that the advice contained within the guidance does not override or replace the individual responsibility of health professionals to make appropriate decisions in the circumstances of their individual patients, in consultation with the patient and/or guardian or carer. This would, for example, include situations where individual patients have other conditions or complications that need to be taken into account in determining whether the NICE guidance is fully appropriate in their case.

Technology Appraisals Endorsement Process

The Department has reviewed its process for the endorsement, implementation, monitoring and assurance of NICE Technology Appraisals in Northern Ireland. The new arrangements are detailed in following circulars, which is effective from 18th December 2013;

NICE Technology Appraisals – Process for Endorsement, Implementation, Monitoring and Assurance in Northern Ireland – HSC (SQSD) 02/13.

For information, details of the previous arrangement can be found on the following circular;

NICE Technology Appraisals and Clinical Guidelines – New Process for Endorsement, Implementation, Monitoring and Assurance in Northern Ireland – HSC (SQSD) 04/11

2024/2025

The following technology appraisals have been endorsed during 2024/25. Information on technology appraisals endorsed in previous years can be found on the homepage.

August 2024

TA992 - Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy

TA990 - Tenecteplase for treating acute ischaemic stroke

TA988 - Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis

TA986 - Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over

July 2024

TA985 - Selective internal radiation therapy with QuiremSpheres for treating unresectable advanced hepatocellular carcinoma

Note this guidance partially updates NICE Technology Appraisal TA688, endorsed by the DoH in April 2021

June 2024

TA983 - Pembrolizumab with trastuzumab and chemotherapy for untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma

TA981 - Voxelotor for treating haemolytic anaemia caused by sickle cell disease

TA979 - Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation

TA977 - Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over

TA975 - Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under

Note this guidance updates and replaces NICE Technology Appraisal TA554, endorsed by the DoH in March 2019.

TA974 - Selinexor with bortezomib and dexamethasone for previously treated multiple myeloma

TA973 - Atogepant for preventing migraine

TA971 - Remdesivir and tixagevimab plus cilgavimab for treating COVID-19

May 2024

TA970 - Selinexor with dexamethasone for treating relapsed or refractory multiple myeloma after 4 or more treatments

TA967 - Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and over

Note this guidance partially updates and replaces NICE Technology Appraisal TA540, endorsed by the DoH in March 2019.

TA964 - Cabozantinib with nivolumab for untreated advanced renal cell carcinoma

April 2024

TA963 - Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency

TA962 - Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy

Note this guidance updates and replaces NICE Technology Appraisal TA598, endorsed by the DoH in September 2019.

TA959 - Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis

TA958 - Ritlecitinib for treating severe alopecia areata in people 12 years and over

TA957 - Momelotinib for treating myelofibrosis-related splenomegaly or symptoms

TA955 - Dupilumab for treating moderate to severe prurigo nodularis

TA953 - Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema

Note this guidance updates and replaces NICE Technology Appraisals TA613, endorsed by the DoH in December 2019 and TA301, endorsed by the DoH in December 2013.